An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit
Phase of Trial: Phase I
Latest Information Update: 02 May 2018
At a glance
- Drugs BI 894999 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim
- 16 Apr 2018 Planned primary completion date changed from 5 Apr 2018 to 19 Apr 2018.
- 05 Mar 2018 Planned primary completion date changed from 15 Mar 2018 to 5 Apr 2018.
- 02 Feb 2018 Planned primary completion date changed from 30 Jan 2018 to 15 Mar 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History